The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: A study on levetiracetam

Seizure

Volumn 15, Issue 6, 2006, Pages 405-408

  Mula, Marco ^a,b   Sander, Josemir W ^a   Trimble, Michael R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antiepileptic drugs; cognition; Depression; Epilepsy; Hippocampal sclerosis; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADULT; AGE DISTRIBUTION; AGGRESSION; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REGIMEN; FEMALE; HIPPOCAMPAL SCLEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT SELECTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; TEMPORAL LOBE EPILEPSY;

ADULT; ANTICONVULSANTS; COGNITION DISORDERS; DEPRESSION; EPILEPSY, TEMPORAL LOBE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; PIRACETAM; SCLEROSIS;

EID: 33746921988     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.05.004     Document Type: Article

References (28)

1. Engel Jr. J. Mesial temporal lobe epilepsy: What have we learned?. Neuroscientist 7 (2001) 340-352
2. Duncan J.S., and Sagar H.J. Seizure characteristics, pathology, and outcome after temporal lobectomy. Neurology 37 (1987) 405-409
3. French J.A., Williamson P.D., Thadani V.M., Darcey T.M., Mattson R.H., Spencer S.S., et al. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 34 (1993) 774-780
4. Martin R., Dowler R., Ho S., Gilliam F., Faught E., Morawetz R., et al. Cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis. Neurology 53 (1999) 709-715
5. Frodl T., Meisenzahl E.M., Zetzsche T., Born C., Groll C., Jäger M., et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 159 (2002) 1112-1118
6. Quiske A., Helmsteadter C., Lux S., and Elger C.E. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 391 (2000) 121-125
7. Mula M., Trimble M.R., and Sander J.W. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 44 (2003) 1573-1577
8. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 4 (2003) 2079-2088
9. Shorvon S.D., and Van Rijckevorsel K. A new antiepileptic drug. J Neurol Neurosurg Psychiatry 72 (2002) 426-428
10. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 (2004) 9861-9866
11. Mula M., Trimble M.R., Yuen A., Liu R.S., and Sander J.W. Psychiatric adverse events during levetiracetam therapy. Neurology 61 (2003) 704-706
12. Duncan J.S. Imaging and epilepsy. Brain 120 (1997) 339-377
13. Recommendations for neuroimaging of patients with epilepsy. Commission on Neuroimaging of the International League Against Epilepsy. Epilepsia 1997; 38:1255-1256.
14. Commission on classification and terminology of the International League Against Epilepsy. Proposal for a revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
15. Mula M., Trimble M.R., Lhatoo S.D., and Sander J.W. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44 (2003) 659-663
16. Mula M., Trimble M.R., Thompson P., and Sander J.W. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60 (2003) 1104-1107
17. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. 35 (1997) 241-256
18. Kuzniecky R., Hetherington H., Ho S., Pan J., Martin R., Gilliam F., et al. Topiramate increases cerebral GABA in healthy humans. Neurology 51 (1998) 627-629
19. Martin R., Kuzniecky R., Ho S., Hetherington H., Pan J., Sinclair K., et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52 (1999) 321-327
20. Kuzniecky R., Ho S., Pan J., Martin R., Gilliam F., Faught E., et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58 (2002) 368-372
21. Ketter T.A., Post R.M., and Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53 5 Suppl. 2 (1999) S53-S67
22. Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 40 Suppl. 10 (1999) S65-S70
23. Levinson D.F., and Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 53 (1999) 1503-1511
24. Trimble M.R., Rusch N., Betts T., and Crawford P.M. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 9 (2000) 249-254
25. Aldenkamp A.P. Effects of antiepileptic drugs on cognition. Epilepsia 42 Suppl 1 (2001) 46-49
26. Neyens L.G.J., Alpherts W.C.J., and Aldenkamp A.P. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuro-Psychopharmacol Biol Psychiatry 19 (1995) 411-419
27. Canevini M.P., Chifari R., and Piazzini A. Improvement of a patient with stuttering on levetiracetam. Neurology 59 (2002) 1288
28. Wheless J.W., and Ng Y.T. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 17 (2002) 413-415